A new trading day began on Monday, with Inozyme Pharma Inc (NASDAQ: INZY) stock price down -6.05% from the previous day of trading, before settling in for the closing price of $2.81. INZY’s price has ranged from $2.61 to $7.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -16.46%. With a float of $43.50 million, this company’s outstanding shares have now reached $61.77 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is 55.92%, operating margin of -5043.98%, and the pretax margin is -4883.3%.
Inozyme Pharma Inc (INZY) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Inozyme Pharma Inc is 32.28%, while institutional ownership is 63.25%. The most recent insider transaction that took place on Apr 02 ’24, was worth 52,210. In this transaction CEO of this company sold 7,523 shares at a rate of $6.94, taking the stock ownership to the 20,665 shares.
Inozyme Pharma Inc (INZY) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.35 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.10% during the next five years compared to -35.73% drop over the previous five years of trading.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Here are Inozyme Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Inozyme Pharma Inc (INZY)
Looking closely at Inozyme Pharma Inc (NASDAQ: INZY), its last 5-days average volume was 0.47 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 7.45%. Additionally, its Average True Range was 0.26.
During the past 100 days, Inozyme Pharma Inc’s (INZY) raw stochastic average was set at 0.83%, which indicates a significant decrease from 1.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.16% in the past 14 days, which was lower than the 61.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.60, while its 200-day Moving Average is $5.07. However, in the short run, Inozyme Pharma Inc’s stock first resistance to watch stands at $2.81. Second resistance stands at $2.99. The third major resistance level sits at $3.08. If the price goes on to break the first support level at $2.54, it is likely to go to the next support level at $2.45. Now, if the price goes above the second support level, the third support stands at $2.27.
Inozyme Pharma Inc (NASDAQ: INZY) Key Stats
With a market capitalization of 177.15 million, the company has a total of 64,240K Shares Outstanding. Currently, annual sales are 0 K while annual income is -71,170 K. The company’s previous quarter sales were 0 K while its latest quarter income was -24,570 K.
